Phaim Pharma

Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform.

The platform is designed to reset the immune system by reintroducing disease-specific antigenic epitopes, suppressing the autoaggressive T cell responses that underlie conditions such as type 1 diabetes.

The company's lead programme targets type 1 diabetes, with a companion biomarker kit in development to identify at-risk individuals and guide patient selection for clinical studies.